Last updated on January 2017

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention


Brief description of study

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention

Detailed Study Description

Receive AGN-241689 or Placebo for the prevention of episodic migraines

Clinical Study Identifier: TX147218

Find a site near you

Start Over

Clinical Research of South Florida

370 Minorca Avenue Coral Gables, FL USA
  Connect »